Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

5-MAPDB

This article is a stubmissing:
Subjective Effects
Interactions
Tolerance
Legality
5-MAPDB molecule structure5-MAPDB molecule structure
5-(2-methylaminopropyl)-2,3-dihydrobenzofuran
Open in Piru
Psychoactive Class
EntactogenStimulant (mild)
Chemical Class
Benzofuran (dihydrobenzofuran)

5-MAPDB is a dihydrobenzofuran analogue of MDMA1 and has mild stimulant properties. In monoamine uptake transporter assays, it inhibited SERT in the 1–3 micromolar concentration range, similar to MDMA1 and is structurally related to 5-MAPB and 5-APDB2. The substance is suspected to carry neurotoxicity concerns similar to those associated with MDMA, although this risk remains uncertain.

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~50 mg
Light50-75 mg
Moderate75-120 mg
Strong120-150 mg
Heavy150+ mg

Duration

Onset45-70 minutes
After Effects2-4 hours
Total5-8 hours

Subjective Effects

Subjective Effects not written up yet

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
white → brown2
Mecke(ME)
white → brown2 → brown3
Mandelin(MD)
yellow2 → black3
Liebermann(LB)
white → black3
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

5-MAPDB is a relatively selective serotonin releaser.3 It has weaker releasing actions on other monoamines and also acts as an agonist at the 5-HT2 receptor family.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Toxicity

Central Nervous System

Suspected neurotoxicity concerns similar to MDMA, though specific data for 5-MAPDB is not established.

History & Culture

In June 2013, the United Kingdom temporarily classified 5-MAPDB as a banned drug alongside nine related compounds. Although it had not been sold as a street drug, authorities acted preemptively because of concerns that it could produce effects similar to 5-APB, which had already been widely sold, and might otherwise become used recreationally.

Legality

Legality not written up yet

References

Source Pages

  1. Bluelight discussion thread: '5-MAPDB – dosage & effects'
  2. Bluelight discussion thread: ‘5-MAPDB – dosage & effects’
  3. Erowid: Experience Vaults – 5-MAPDB Reports (accessed 2025)
  4. Wikipedia

Citations

  1. Pharmacological profile of novel psychoactive benzofurans. British Journal of Pharmacology / PMC (2015). https://doi.org/10.1111/bph.1311912
  2. The challenge of New Psychoactive Substances: A technical update. United Nations Office on Drugs and Crime / Drugs and Alcohol Ireland (2024). https://www.drugsandalcohol.ie/41195/1/The_Challenge_of_NPS_A_technical_update_2024.pdf1
  3. Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. ResearchGate (2019). https://doi.org/10.1007/s00213-018-5059-51

Further Reading

  1. ACMD UK, 'Benzofuran Report' (2014) – Annex on 5-MAPDB
  2. Monte et al. (1993) Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues
  3. Monte et al. (2013) Synthesis and characterization of MAPDB isomers
  4. Rickli et al. (2015) Pharmacological profile of novel psychoactive benzofurans
  5. Shimshoni et al. (2017) Pharmacological evaluation of 5-MAPDB and related analogues
  6. Liu et al. 2016 - Identification of five substituted phenethylamine derivatives 5‐MAPDB, 5‐AEDB, MDMA methylene homolog, 6‐Br‐MDMA, and 5‐APB‐NBOMe

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 5-MAPDB article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.